Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruth Lopert

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Open Medicine : a Peer-Reviewed, Independent, Open-Access Journal|May 24, 2011
Toward a definition of pharmaceutical innovationSteven Morgan, Ruth Lopert, Devon Greyson
Health Policy (Amsterdam, Netherlands)|February 18, 2014
Reply by authorsDeborah Gleeson, Ruth Lopert, Papaarangi Reid
Health Policy (Amsterdam, Netherlands)|August 20, 2013
Applying rapid 'de-facto' HTA in resource-limited settings: experience from RomaniaRuth Lopert, Francis Ruiz, Kalipso Chalkidou
Australian and New Zealand Journal of Public Health|October 13, 2015
Pharma's next frontier? New threats to public health in the Regional Comprehensive Economic Partnership agreementBelinda Townsend, Deborah Gleeson, Ruth Lopert
Health Policy (Amsterdam, Netherlands)|September 3, 2013
How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New ZealandDeborah Gleeson, Ruth Lopert, Papaarangi Reid
Asia-Pacific Journal of Public Health|December 7, 2016
The Regional Comprehensive Economic Partnership, Intellectual Property Protection, and Access to MedicinesBelinda Townsend, Deborah Gleeson, Ruth Lopert
The Medical Journal of Australia|April 3, 2015
Costs to Australian taxpayers of pharmaceutical monopolies and proposals to extend them in the Trans-Pacific Partnership AgreementDeborah H Gleeson, Hazel Moir, Ruth Lopert
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 1, 2007
Prices for innovative pharmaceutical products that provide health gain: a comparison between Australia and the United StatesElizabeth E Roughead, Ruth Lopert, Lloyd Norman Sansom
Global Social Policy|May 1, 2018
The Trans Pacific Partnership Agreement, intellectual property and medicines: Differential outcomes for developed and developing countriesDeborah Gleeson, Joel Lexchin, Ruth Lopert, et al.
Health Affairs (Project Hope)|October 9, 2013
Biosimilars and the European experience: implications for the United StatesFrancis Megerlin, Ruth Lopert, Ken Taymor, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Open Medicine : a Peer-Reviewed, Independent, Open-Access Journal|May 24, 2011
Toward a definition of pharmaceutical innovationSteven Morgan, Ruth Lopert, Devon Greyson
Health Policy (Amsterdam, Netherlands)|February 18, 2014
Reply by authorsDeborah Gleeson, Ruth Lopert, Papaarangi Reid
Health Policy (Amsterdam, Netherlands)|August 20, 2013
Applying rapid 'de-facto' HTA in resource-limited settings: experience from RomaniaRuth Lopert, Francis Ruiz, Kalipso Chalkidou
Australian and New Zealand Journal of Public Health|October 13, 2015
Pharma's next frontier? New threats to public health in the Regional Comprehensive Economic Partnership agreementBelinda Townsend, Deborah Gleeson, Ruth Lopert
Health Policy (Amsterdam, Netherlands)|September 3, 2013
How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New ZealandDeborah Gleeson, Ruth Lopert, Papaarangi Reid
Asia-Pacific Journal of Public Health|December 7, 2016
The Regional Comprehensive Economic Partnership, Intellectual Property Protection, and Access to MedicinesBelinda Townsend, Deborah Gleeson, Ruth Lopert
The Medical Journal of Australia|April 3, 2015
Costs to Australian taxpayers of pharmaceutical monopolies and proposals to extend them in the Trans-Pacific Partnership AgreementDeborah H Gleeson, Hazel Moir, Ruth Lopert
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 1, 2007
Prices for innovative pharmaceutical products that provide health gain: a comparison between Australia and the United StatesElizabeth E Roughead, Ruth Lopert, Lloyd Norman Sansom
Global Social Policy|May 1, 2018
The Trans Pacific Partnership Agreement, intellectual property and medicines: Differential outcomes for developed and developing countriesDeborah Gleeson, Joel Lexchin, Ruth Lopert, et al.
Health Affairs (Project Hope)|October 9, 2013
Biosimilars and the European experience: implications for the United StatesFrancis Megerlin, Ruth Lopert, Ken Taymor, et al.
Pageof 5